Your Biotech Firm Runs on Sensitive Data. OpenClaw Automates Workflows Without Exposing It.

FDA submissions, IND applications, and compliance filings require pulling data from multiple sources, formatting it correctly, and routing drafts through legal review. One missed attachment or formatting error delays the entire submission timeline.

Quarterly updates to investors and board members require gathering pipeline progress, financial summaries, milestone status, and team updates from across departments. The CEO or COO spends days compiling what should be a routine communication.

Research updates from lab teams often sit in email threads or Slack channels that executives never check. Critical findings get buried. Decisions that need leadership input stall because the right information never reaches the right person.

Researchers and partners share protocols, compound data, and unpublished findings through consumer email and file-sharing tools with no audit trail. In a regulated industry where one compliance violation can delay a filing or jeopardize a partnership, every uncontrolled data transfer is a liability.

Contract research organizations, manufacturing partners, and suppliers communicate through scattered email chains. Status updates get missed. Deliverable deadlines slip because nobody has a single view of what is pending and from whom.

Processes that worked for a 15-person team collapse at 50. Approval chains get longer, document routing gets confused, and nobody knows who owns what. Without digital infrastructure for operational workflows, biotech companies accumulate process debt that slows every department down.

OpenClaw pulls pipeline milestones, financial highlights, and team updates from your documents and email, then assembles a draft investor update in your preferred format. Review and send instead of building from scratch every quarter.

OpenClaw monitors submission deadlines, routes draft documents to the right reviewers, and flags missing components before filing dates. Every regulatory document moves through a defined workflow instead of sitting in someone's inbox.

OpenClaw scans incoming emails and messages, categorizes them by urgency and topic (lab results, vendor updates, legal requests), and routes each to the right person. Sensitive communications stay on your server. Nothing goes through third-party sorting tools.

OpenClaw sends automated status check-ins to CROs, CMOs, and suppliers at defined intervals. Responses get logged and summarized. Overdue deliverables get flagged to the project lead automatically, without anyone chasing emails.

Before SAB meetings, investor calls, or partnership discussions, OpenClaw compiles a briefing package from your documents: pipeline status, competitive landscape notes, regulatory timeline, and key talking points. Delivered to your inbox the morning of.

OpenClaw routes purchase requests, vendor invoices, and contract approvals to the right person based on department, amount, and project. Approved items move forward automatically. Stalled approvals get escalated. No more chasing signatures through email or Slack.

Mixbit documents your document routing paths, regulatory submission timelines, CRO coordination cadences, and internal communication patterns. Every automation is designed around how your biotech firm actually operates, not a generic business template.

OpenClaw gets configured with biotech-specific workflows: regulatory document tracking connects to your filing calendar, investor update assembly pulls from your actual data sources, and communication triage follows your team's routing logic. Nothing is off-the-shelf.

After go-live, Mixbit monitors workflow performance and adjusts automation rules based on real usage. As your team grows from pre-clinical to clinical to commercialization, OpenClaw scales with you: new approval chains, additional CRO partnerships, expanded regulatory workflows, and more integrations, all without rebuilding from scratch.